FDA-Approved Uses of Cord Blood

The important point is that cord blood is already a real transplant input for mainstream blood and immune disorders, not a speculative future therapy. In FDA labeling, cord blood products are approved for hematopoietic and immunologic reconstitution in diseases of the blood forming system. In practice, that means leukemias, lymphomas, marrow failure, immune deficiencies, sickle cell disease, and inherited metabolic disorders, which adds up to roughly the 75 to 85 disease range often cited across transplant organizations.

• FDA approval is broad by disease family, not a separate product approval for each illness. Licensed HPC, Cord Blood products are indicated for disorders affecting the hematopoietic system that are inherited, acquired, or caused by myeloablative treatment, which covers many individual diagnoses under one transplant category.
  1 fda 2 fda
• The current standard use case is mostly blood cancers and other serious blood disorders. NMDP lists leukemia, lymphoma, severe aplastic anemia, severe combined immunodeficiency, sickle cell disease, Wiskott Aldrich syndrome, and inherited metabolic disorders among transplant treated diseases, and its transplant data shows cord blood being used across malignant and non malignant indications.
  3 nmdp 4 nmdp
• This also explains the gap between approved use and experimental use. FDA consumer guidance says approved cord blood uses are for blood forming system disorders, while the interview references a much larger set of ongoing trials for conditions outside that core transplant lane, where evidence is still being built.
  2 fda 5 sacra

Going forward, cord blood is likely to keep moving along two tracks. One is steady expansion inside established transplant medicine, as seen with the December 8, 2025 FDA approval of Omisirge for severe aplastic anemia. The other is a broader clinical trial pipeline that could push cord blood beyond classic blood disorders if enough studies convert into labeled uses.